Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448795 | 0.85 | KAT6A (0.54) | ALDH1A1TLR7LMNASMN1; SMN2NPC1 | |
| SCHEMBL6448406 | 0.85 | TLR7 (0.56) | L3MBTL1ALDH1A1TLR7LMNASMN1; SMN2 | |
| SCHEMBL6467701 | 0.84 | SMN1; SMN2 (0.54) | L3MBTL1ALDH1A1POLBLMNASMN1; SMN2 | |
| SCHEMBL6449862 | 0.83 | GAA (0.62) | L3MBTL1ALDH1A1ALOX12POLBLMNA | |
| SCHEMBL6449112 | 0.80 | NPC1 (0.49) | L3MBTL1ALDH1A1ALOX12POLBLMNA | |
| SCHEMBL15988767 | 0.79 | CTNNB1 (0.57) | ALDH1A1ALOX12DHODHHDAC6CNR2 | |
| SCHEMBL6451241 | 0.75 | TMPRSS4 (0.51) | L3MBTL1ALDH1A1ALOX12TLR7POLB | |
| SCHEMBL2650229 | 0.74 | POLB (0.72) | L3MBTL1ALDH1A1POLBSMN1; SMN2NPC1 | |
| SCHEMBL7047527 | 0.74 | P2RX7 (0.47) | TLR7LMNAGAACNR2 | |
| SCHEMBL15988764 | 0.74 | CTNNB1 (0.64) | DHODHHDAC6CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | L3MBTL1 4366/4885ALDH1A1 287/4885ALOX12 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.